Stem Cells and Cardiac Repair by Leontiadis, Evangelos et al.
18
HOSPITAL CHRONICLES, SUPPLEMENT 2006 MYOCARDIAL REGENERATION
19
Stem Cells and Cardiac Repair
Evangelos Leontiadis, MD, Athanassios Manginas, MD, 
Dennis V. CokkinosMD
A B S T R A C T
Contrary to the initial belief that the heart is a terminally differentiated organ that 
cannot replace its own cell damage, there is now proof that the circulating blood pro-
vides the injured tissue with adult stem and progenitor cells, which have the potential 
to differentiate into cardiomyocytes and ultimately improve cardiac function. Thus, 
transplantation of stem cells into the myocardium in patients with severe myocardial 
dysfunction post-myocardial infarction is being currently investigated for experimen-
tal as well as for clinical purposes. Many issues regarding the mode of action remain 
to be elucidated. The BOOST trial was the first completed, randomized study that 
showed safety, feasibility and efficacy of the method. However, a more recent double-
blind, placebo-controlled study failed to reveal an increase in global left ventricular 
ejection fraction and cast doubt on the efficacy of the method. Thus, further random-
ized studies are needed to evaluate this novel approach in the treatment of ischemic 
heart failure and determine its role, safety and efficacy.
Until recently it was believed that the heart is a terminally differentiated organ 
with no ability to repair any tissue injury. However, recent evidence suggests [1-4] 
that the myocardium may have some potential to repair its own tissue injury, but this 
regenerative ability is limited and can only repair minor cardiomyocyte damage. Any 
tissue loss that outbalances the regenerative and self-renewing properties of the heart 
would lead to an overt clinical picture of heart failure.
The healing process of the myocardium is undertaken by cardiac stem cells, the 
origin of which is a subject of debate. These cells might represent either local resident 
cardiac stem cells [3-9] that have been suggested to differentiate into cardiomyocytes 
or bone marrow derived stem cells that reside in the myocardium as part of the natu-
ral myocardium homeostasis mechanism or in response to tissue damage [10-12]. In 
a recent report by Laugwitz and colleagues [7], an endogenous cardiac progenitor 
(cardioblast) was identified in the postnatal rat, mouse and human myocardium. This 
cell is capable of obtaining a mature cardiomyocyte phenotype, expressing myocytic 
markers and generating action potentials. The epicardium has also been suggested 
as a potential source of cardiac stem cells, which then migrate into the myocardium 
and transdifferentiate into multiple cell lines [13].
Cardiac repair is a very complex and not fully understood mechanism that com-
prises many interacting steps. Certain cytokines play a critical role in this cascade, 
that act as mediators of this complex process. Damaged tissue secretes stem cell factor 
(SCF), CXCR4, stromal-derived factor-1 (SDF-1), granulocyte colony stimulating fac-
tor (G-CSF), vascular endothelial growth factor (VEGF), monocyte chemoattractant 
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proteins-1 (MCP-1) and other substances, which determine the 
mobilization and recruitment of stem/progenitor cells to the 
injury site in the periphery. Homing of the activated stem cells 
to the injury site is the next crucial step as they adhere to the 
activated endothelium, migrate through the endothelial cells 
and finally invade and home in the damaged myocardium. 
The final step of this cascade is the transdifferentiation of the 
integrated stem cells, which is a process determined not only 
by their genetic material but also but the microenviroment 
they are attracted to [14-16].
With all experimental data showing improvement of 
cardiac function after stem cell and skeletal myoblast trans-
plantation, regardless of the exact mode of action, the next 
logical step was the conduction of studies in humans. Most 
of them were small, uncontrolled and nonrandomized, thus 
causing difficulties in estimating the exact role of cardiac re-
pair therapy in patients with acute or chronic coronary artery 
disease [10,11,17-20].
A .  P A T I E N T S  W I T H  N O N - V I A B L E ,  
C H R O N I C A L L Y  I S C H E M I C  
C A R D I O M Y O P A T H Y
In patients with chronic ischemic cardiomyopathy as a 
result of postinfarction scars, Pagani and colleagues injected 
autologous skeletal myoblasts intramyocardially in 5 patients 
awaiting heart transplantation during left ventricular assist 
device (LVAD) implantation. Examination of the hearts from 
3 patients who finally underwent transplantation and from 
one who succumbed revealed development of myotubes in the 
scarred myocardium.21 Menasche and colleagues implanted 
autologous skeletal myoblasts intramyocardially (in-scar in-
jection) in 10 patients with severely depressed left ventricular 
(LV) function (LV ejection fraction-EF <35%) during coro-
nary artery bypass grafting (CABG) surgery. Bypass grafting 
was carried out in noninjected territories only. Almost one 
year later he reported an improvement in regional wall mo-
tion and global LVEF, but 4 patients had to undergo cardio-
verter-defibrillator implantation due to episodes of sustained 
ventricular tachycardia [22].
Almost similar in design was the study by Siminiak and 
colleagues [23], who also combined CABG surgery, with graft-
ing both injected and noninjected territories, in 10 patients 
with severely compromised LV function and intramyocardial 
skeletal myoblast injection in the akinetic/dyskinetic areas. 
Four months later there was an improvement in regional and 
global contractility, which was sustained over a period of 
12 months. Ventricular arrhythmias, especially in the early 
postoperative stage, were also a serious concern in this group 
of patients.
Autologous skeletal myoblasts were also injected intra-
myocardially by 2 other groups and were also combined with 
surgical revascularization treatment. Herreros and colleagues 
[24] treated 11 patients while revascularizing both injected 
and noninjected segments, whereas Chachques and colleagues 
[25] treated 20 patients in combination with revascularization 
of the noninjected territories only. Both groups reported an 
improvement in regional and global contractility as well as 
enhancement of viability in the injected area. An interesting 
finding in the former study was the lack of cardiac arrhythmias 
and especially ventricular tachyarrhythmias in contrast to the 2 
aforementioned studies by Pagani and Menasche. This finding 
is probably associated with the selection of patients with higher 
baseline LVEF and to the effect of revascularisation on the 
infarcted myocardial segments during CABG surgery.
The percutaneous, transendocardial route reported by 
Smits [26] consisted of targeted intramyocardial injection of 
autologous skeletal myoblasts guided by electromechanical 
mapping. This group treated 5 patients with heart failure 
and after a follow-up period of 6 months, cell transplanta-
tion resulted in an increase of LVEF and improvement of 
wall thickening at areas of injection. This technique was 
also complicated by serious ventricular arrhythmias or even 
reported sudden deaths, that made the implantation of cardio-
verter-defibrillator (ICD) mandatory. Siminiak and colleagues 
[27] applied in a phase I trial a novel technique of trans-coro-
nary-venous for skeletal myoblast transplantation (TransAc-
cess catheter system) in 9 patients with akinetic/dyskinetic 
scar tissue and moderately depressed LVEF. The process was 
feasible and safe, but he only reported an improvement of 
New York Heart Association (NYHA) functional class and a 
nonsignificant LVEF increase in a period of 6 months.
A recent study of a 4-year follow-up [28] in 30 patients 
who underwent in-scar injection of skeletal myoblasts during 
CABG surgery (n=24) or LVAD implantation (n=6) reported 
new evidence of cell viability in the region of myocardial scar, 
an increase in LVEF (from 28% at baseline to 36% at 2 years) 
and a reduction in LV dimensions. However, these results 
on cardiac function should be interpreted with caution since 
skeletal myoblast transplantation was associated with bypass 
surgery. Histological analysis of 4 of 6 patients from the 
LVAD arm who underwent heart transplantation revealed 
survival of skeletal myoblasts in the infarcted myocardium, 
minimal localized migration of myoblasts and myofiber for-
mation. The procedure was safe, with absence of increased 
arrhythmogenicity and deaths in the follow-up period that 
could be attributed to cell therapy. The only procedure-related 
arrhythmia was nonsustained ventricular tachycardia in 3 of 
24 CABG patients and was managed with medications and 
ICD implantation.
Only a few groups used bone marrow derived cells for 
transplantation in this cohort of patients with chronic ischemic 
heart failure and postinfarction scars. Stamm and colleagues 
[29,30] injected selected CD133+ bone marrow stem cells 
along the infarct border zone during CABG surgery in patients 
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with depressed LVEF. These studies were safe and resulted 
in improvement of perfusion in the cell-treated area, global 
LVEF and favorable LV remodeling.
Strauer and colleagues reported recently the results of 
the IACT study, which showed a favorable effect of intra-
coronarilly (in the infarct-related artery) infused unselected 
bone marrow derived mononuclear cells on functional and 
metabolic regeneration of chronic, non-viable myocardial 
infarction (MI). This study included also a nonrandomized 
control group. Cell therapy which was applied in 18 patients 
resulted in an improvement of global and regional LV func-
tion, reduction of infarct size and enhanced regional viability 
of the infarcted tissue 3 months later. There was no evidence 
of arrhythmia exacerbation and only one patient (out of the 18 
treated) showed significant restenosis which was successfully 
treated with stent implantation [31].
Thus, in the clinical setting of nonviable, postinfarction 
scarred myocardium, most studies conducted are small, non-
randomized and used intramyocardial injection of skeletal 
myoblasts, with surgical or percutaneous approach. Most of 
them showed increase in LVEF and regional contractility but 
the effects of the cell treatment should be assessed cautiously 
due to the concomitant revascularization procedure. Increased 
arrhythmogenicity, including ventricular dysrrhythmias and 
deaths also raises concern about the potential for widespread 
use. Recent work presenting use of bone marrow-derived se-
lected or unselected stem cells in the same clinical setting also 
seem efficacious without any serious side effects.
B .  P A T I E N T S  W I T H  C H R O N I C A L L Y  
I S C H E M I C  B U T  V I A B L E  M Y O C A R D I U M
Hamano and colleagues [32], for the first time, injected 
intramyocardialy autologous unselected bone marrow-derived 
mononuclear cells during CABG in 5 patients with old MI and 
chronic, severe ischemic cardiomyopathy. After 12 months, 
they reported enhancement of myocardial perfusion and the 
safety of the method. In the next 2 studies published in 2003, 
autologous unselected bone marrow stem cells (BMSCs) were 
injected transendocardially (guided by electromechanical 
mapping) in small, uncontrolled studies. At 3 months, all pa-
tients experienced less angina attacks and enhanced myocardi-
al perfusion [33,34], while magnetic resonance imaging (MRI) 
also revealed improved regional wall motion in the injected 
areas [33]. In the only study with a nonrandomized control 
group [35]., Perin and colleagues also used the percutaneous 
transendocardial (electromechanically guided) approach in 
14 patients with severe, chronic ischemic heart failure with 
a mean LVEF of 30%. Two months later, they reported less 
angina attacks, improved NYHA functional class, enhance-
ment of perfusion, regional wall motion, global LVEF and a 
significant reduction in left ventricular end-systolic volume in 
the cell treated group. One patient died 3 months after cell 
treatment. A recent report from this group [36] focuses on the 
postmortem analysis of the heart of one patient who received 
cell therapy. In the cell treated myocardium, enhanced angio-
genesis was present, partially combined with a special pericyte 
population, which was located in areas suggesting migration 
towards adjacent bundles of cardiomyocytes. These pericytes 
were characterized not only by the presence of cytoskeletal 
elements and contractile proteins (troponin, sarcomeric á-ac-
tinin, actinin) but also by the expression of specific myocardial 
proteins, suggesting a partial transdifferentiation.
A recent randomized, double-blind placebo-controlled 
study [37] assessed the impact of intracoronarilly delivered 
blood-derived circulating progenitor cells (mobilized with 
G-CSF) combined with recanalization of chronic coronary 
total occlusion on hibernating myocardium. At 3 months, 
coronary flow reserve in the reperfused artery improved, 
the number of hibernating myocardial segments treated 
declined, the infarct size was reduced and LVEF increased 
significantly in the treatment group. Of note that no serious 
adverse events were reported including in-stent reocclusion 
or in-stent restenosis.
Thus, in the setting of chronic, severe hibernating and/or 
ischemic cardiomyopathy, transendocardial (electromechani-
cally guided) approach seems to increase myocardial perfusion 
and probably regional wall motion, but only two studies [35,37] 
showed an increase in global LVEF. All studies reported sub-
stantial relief from angina pectoris, but this could be attributed 
to a significant placebo effect. This technique seems to be 
feasible and safe, but final conclusions cannot be drawn from 
these small, uncontrolled studies.
C .  P A T I E N T S  I N  T H E  E A R L Y  P O S T I N -
F A R C T I O N  P E R I O D
The most widely investigated clinical scenario however 
concerns patients during the early postinfarction period, 
who undergo percutaneous coronary intervention (PCI) and 
stent implantation of the infarct related artery (IRA), through 
which several days later selected or unselected BMSCs are 
infused. Strauer and colleagues [38], delivered in 10 patients 
intracoronarilly-via the central lumen of an over-the-wire sys-
tem- unselected BMSCs, 5-9 days post MI, whereas 10 other 
patients served as a nonrandomized control group. Three 
months later they reported a decrease in the infarct size and 
an increase in myocardial perfusion and improvement in re-
gional wall motion, while global LVEF and LV dimensions 
remained unchanged.
Another group that used unselected bone marrow stem 
cells and a nonrandomized control group was that of Fernan-
dez-Aviles and colleagues. They also delivered (in 20 patients) 
mononuclear cells intracoronarily almost 2 weeks after MI. 
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At 6 months, they reported an improvement in regional wall 
motion, global LVEF, LV endsystolic volume and increased 
thickness of the infarcted wall [39].
Assmuss and colleagues [40] administered intracoronarily 
BMSCs almost 4 days after MI and subsequent PCI with stent 
implantation. Eleven patients received circulating blood-de-
rived progenitor cells (CPCs), 9 patients received bone mar-
row-derived mononuclear cells (BMCs) and 11 patients served 
as a nonrandomized, control group. At 4 months follow-up, 
they reported a significant increase in global LVEF, regional 
wall motion in the infarcted territory, coronary flow reserve 
of the infarct related artery, the viability of the infarcted seg-
ment and also improvement of the LV end-systolic volumes 
in both cell treated groups compared to the control group. 
Of note that no malignant arrhythmias in either cell-treated 
group were observed and that there was no difference in the 
above mentioned parameters between the two different cell 
groups administered.
In the context of the same study, Schachinger and col-
leagues [41] also reported a sustained improvement in LV 
remodeling and cardiac function in patients randomized to 
intracoronary infusion of either circulating blood-derived 
progenitor cells (30 patients) or bone marrow-derived mono-
nuclear cells (29 patients) as a complementary therapy to 
stenting of the IRA. At 4 months, quantitative LV angiog-
raphy revealed a significant increase in LVEF and reduction 
in LV end-systolic volumes with no difference between the 2 
cell groups. Cardiac performance was also assessed by MRI 
at 4 and 12 months after cell treatment. Interestingly, global 
LVEF not only improved significantly in the first 4 months, 
but increased further in the next 8 months, thus resulting in a 
total increase of almost 9% one year after cell therapy.
Another group administered selected BMSCs, namely 
MSCs, via the intracoronary route in the infarct related ar-
tery 18 days after MI and subsequent PCI [42]. Thirty-four 
patients were randomized for cell therapy (4.8-6x1010 cells) and 
35 for the control group. At 3-6 months follow-up, the cell-
treated group showed a decrease in the size of the infarction, 
LV dimensions and an improvement in regional and global 
contractility. Even though intracoronary delivery of MSCs in 
dogs [43] was associated with “microinfarctions” due to the 
size of this particular cell type, this study did not report any 
periprocedural adverse events. Autologous culture-expanded 
MSCs combined with EPCs were administered intraconon-
arilly also by another group in patients with both recent and 
old anteroseptal MIs [44]. Four months after cell therapy, 
they reported an uneventful course and partial improvement 
in contractility and viability in some of previously non-viable 
myocardial segments, but no effect on global LVEF or LV 
remodeling.
Intracoronary infusion of selected BMSCs in patients with 
acute MI and PCI with stenting of the IRA was also reported 
by Bartunek and colleagues [45] who administered 12.6±2.2x 
106 bone marrow-derived CD133 positive progenitor cells in 
19 patients 12 days after acute MI while 16 patients served 
as a nonrandomized control group. At 4 months, there was a 
significant improvement in myocardial perfusion, viability and 
function and absence of stem-cell related arrhythmias in the 
cell-treated group. On the other hand, the cell treated-group 
showed in-stent restenosis (7/19 patients) and reocclusion 
(2/19 patients) as well as significant de novo lesion of the 
IRA (2/19 patients).
In the BOne marrOw transfer to enhance ST-elevation 
infarct regeneration (BOOST) trial, 30 patients received 
2.5±0.9x109 unselected bone marrow-derived nucleated 
cells intracoronarily and 30 patients served as the control 
group Approximately 6 days after successful PCI and stent 
implantation in the IRA [46]. At 6 months, cardiac MRI 
revealed significant improvement of global LVEF in the cell-
treated group due to an increased systolic wall motion of the 
segments adjacent to the infarcted segment. Cell therapy did 
not increase in-stent restenosis, arrhythmogenic complica-
tions or cause microinfarctions. There was no change in LV 
dimensions or viability of the infarcted area. Based on this 
latter finding, Wollert and colleagues attributed the recovery 
of the cardiac function probably to the paracrine effects of 
bone marrow-derived stem cells, and not to their transdif-
ferentiation into cardiomyocytes.
Very recently the benefit of bone marrow-derived un-
selected stem/progenitor cell therapy was questioned in a 
truly randomized, double-blind, placebo-controlled study in 
67 patients after PCI for ST-elevation MI [47]. At 4 months, 
no additive effect of cell therapy was noted on global LV func-
tional recovery in patients with moderately depressed global 
LV function. Whether this novel treatment modality could 
be of practical use in patients with greater myocardial area 
at risk and greater LV dysfunction still has to be elucidated 
with similarly designed trials.
Thus, in the setting of the early postinfarction period clini-
cal trials use mostly unselected bone marrow stem cells via 
the intracoronary over-the wire approach in the IRA. They 
show improvement of regional wall motion contractility of the 
infarcted or the infarct border area, which accounts for the 
enhancement of global LVEF reported in most of them. On 
the other hand, the fact that there are confounding data on the 
actual effect of BMSCs on myocardial perfusion, infarct size 
and LV dimensions, emphasizes the need to further elucidate 
the mechanisms of action of these cells. One important advan-
tage of this cell type is the lack of adverse events and especially 
ventricular arrhythmias or sudden cardiac deaths.
M O B I L I Z A T I O N  O F  S T E M / P R O G E N I T O R  
C E L L S
Based on the knowledge that bone marrow-derived pro-
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TABLE 1. Clinical Studies Using Cytokines for Stem Cell Mobilization
STUDY Clinical setting Patients treated Cell type  Delivery Outcome/Adverse events
   infused route
Kang et al  Onset of G-CSF G-CSF only (10 pts) Peripheral ic Improvement in systolic function and
[62] treatment 4 days  vs apheresis after  collected MNCs  myocardial perfusion (ic cell infusion).
 before PCI for MI  G-CSF (10 pts) (mobilized with  Mild elevation of CPK-MB (ic cell
 (MI 2-270 days old) vs controls G-CSF)  infusion group). Increased rate of
     in-stent restenosis of the IRA (Only
     G-CSF group).
Ince et al  Onset of G-CSF PCI + G-CSF NA NA Improvement in systolic function, LV
[63] treatment 89±35   (25 pts) vs PCI    dimensions and ↓ viability of
 minutes (25 pts)   infarcted tissue; No serious adverse
 after primary PCI    events, including restenosis
Hill et al [64] CCS ≥3, Severe  G-CSF (16 pts) NA NA 2 pts with NSTEMI and MI/death.
 reversible ischemia  vs 15 healthy    No benefit in cardiac function
 (Dobutamine MRI),  subjects
 LVEF 52±2,6% 
Jorgensen  Onset of G-CSF G-CSF treated  NA NA No difference between the 2 groups
et al [65] treatment 30±12 (n=20) vs      in in-stent neo-intimal hyperplasia or
 hours after controls (n=21)   restenosis (IVUS) at 5 months
 primary PCI    invasive follow-up
Boyle et al  Severe reversible  G-CSF (5 pts) vs Peripheral ic Angina ↓, collateral flow grade ↓
 ischemia (SPECT) 5 controls collected  (angiography). No in-stent resteno-
 with CCS ≥3;  CD 34+ cells  sis, but in pts with documented 
 LVEF 50± 4,7%     enhanced collaterals one with Acute
     Coronary Syndrome and one with
     Lentigo maligna of the scalp)
Huettmann  Chronic severe HF, G-CSF treated DCM NA NA Improvement in NYHA class and
et al [67] LVEF<30% pts (n=7) vs G-CSF   6MWT, echo unchanged; Occasional
  treated ICM pts (n=9)   dyspnea, angina and 1 fatal Vfib
  vs controls (ICM, n=8)   (Treated ICM group)
Wang  Severe reversible G-CSF (n=13) vs NA NA Myocardial perfusion unchanged,
et al [68] ischemia (SPECT)  controls (n=16)   LVEF (SPECT: no change, MRI: ↓) 
 with CCS ≥3;    - Improvement in symptoms,
 LVEF 39±13%     NTG use. No adverse events
Kuethe  Onset of G-CSF G-CSF treated  NA NA No serious adverse events. ↓ 
et al [69] treatment PCI 7.6  (n=14)   regional wall motion, perfusion and
 ±5.2 hours after vs. controls (n=9)   LVEF (treatment group). 1/13 
 primary PCI    treated pts with in-stent restenosis
     (angiography)
Pompilio  10 days -3 4 pts (3 with MI Peripheral Trans- 2 pts with follow-up (1 with
et al [70] months after  treated with off-pump collected epicardial perfusion, 1 with viability of the
 MI or large  CABG, 1 with ische- CD133+ cells  infarcted area); No serious adverse
 ischemic areas mia treated with (mobilized  events
  transdiaphragmatic with Lenoga-
  approach) strim)
G-CSF, granulocyte colony-stimulating factor; PCI, percutaneous coronary intervention ; MNC, mononuclear cells; IRA, infarct-related artery; 
LVEF, left ventricular ejection fraction; CCS, Canadian Cardiovascular Society ; SPECT, single photon-emission CT; NTG, nitroglycerin; CABG; 
coronary artery bypass grafting; IVUS; intracoronary intravascular ultrasound; DCM, dilated cardiomyopathy; ICM, ischemic cardiomyopathy; 
NYHA, New York Heart Association; Vfib, Ventricular fibrillation; ic, intracoronary; LV, left ventricle; NSTEMI, Non-ST-elevation myocardial 
infarction
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genitor cells can reach the target organ through peripheral 
blood [47,48] and that tissue repair is mediated by cytokines 
secreted from sites of ischemic injury [16,49-52], an effort 
was made to evaluate the enhancement of the natural repair 
mechanism by exogenous delivery of G-CSF (Granulocyte-
colony-stimulating-factor) and/or other cytokines on cardiac 
repair.
Stem and progenitor cell mobilization with granulocyte 
colony-stimulating factor (G-CSF) and/or stem cell factor 
(SCF) and other cytokines has been shown to improve cardiac 
function after MI in the experimental setting, but results do 
not seem to be uniform in different species or even differing 
human populations. It also seems that the exact mechanism is 
still to be elucidated since early reports on differentiation of 
mobilized stem cells into cardiomyocytes and endothelial cells 
in the infarcted area are challenged by recent experimental 
work. These latter studies reported a direct antiapoptotic ef-
fect of G-CSF on cardiomyocytes and endothelial cells in in-
farcted hearts as well as an accelerated wound healing process 
in the necrotic tissue along with the myocardial regeneration 
effect [10,53-60].
For clinical purposes, G-CSF induced mobilization of 
stem cells offers a more practical and noninvasive approach 
but the increased rate of in-stent restenosis reported in the first 
clinical trial conducted (MAGIC trial) raised great scepticism 
on the safety of the method. However, the late FIRSTLINE-
AMI and STEMMI trials reported a restenosis rate within the 
expected range. This was partly due to a different and more 
strict selection of patients in the latter studies regarding age, 
severity of coronary artery disease, chronicity of myocardial 
infarction and onset of subcutaneous G-CSF delivery after 
PCI of the IRA (Table 1) [61-70].
Our group has administered autologous selected CD 133+ 
stem/progenitor cells via the intracoronary route in 12 patients 
with an old, non-viable anterior wall MI with a LVEF lower 
than 40% [71,72]. These patients underwent echocardio-
graphic and Tl-201 reinjection scintigraphic studies 4.4±2.0 
months (mid-term) and 11.3±3.0 months (long-term) after 
BMSC delivery. We found a progressive and sustained ben-
efit in myocardial perfusion as documented by an increase in 
perfusion ratio in the infarcted anterior wall and apex of the 
left ventricle. Perfusion ratio (calculated as the percentage 
of normalized radioactivity -counts/pixel- in the infarcted 
segment vs maximum Tl-201 uptake) increased during long-
term follow-up by 22.6% (p=0.005) in the anterior wall and 
34.7% in the apex (p<0.001). We also found a progressive and 
gradual effect on LV remodeling as manifested by a decrease 
in end-diastolic and end-systolic volumes of the left ventricle. 
Tissue Doppler imaging performed at 6 months after bone 
marrow transplantation revealed that local deformation 
increased significantly as indicated by the improvement of 
ejection time and maximum strain as well as peak systolic 
strain rate (Table 2).
S U M M A R Y  A N D  C O N C L U S I O N
Transplantation of stem cells for myocardial dysfunction 
after myocardial infarction is being intensively investigated 
for experimental as well as for clinical purposes. Contrary to 
the dogma that the heart is a terminally differentiated organ 
that cannot replace its own cell damage, there is now proof 
that the circulating blood provides the injured tissue with 
adult stem and progenitor cells, which have the potential to 
differentiate into multiple cell lineages and ultimately improve 
cardiac function. Many questions regarding the exact mode 
of action remain unanswered. The BOOST trial was the first 
completed, randomized study that showed safety, feasibility 
and efficacy of the method. The latest study published by 
Janssens and colleagues was the first double-blind, placebo-
controlled study and failed to reveal an increase in global 
LV ejection fraction reported in the former study. Thus, it is 
imperative to conduct more double-blind randomized studies 
in order to evaluate this novel method and its exact role in the 
treatment of ischemic heart failure, but safety should always 
a primary concern.
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